Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of locally recurrent metastatic triple negative breast cancer. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine |